Clinical trial
Pharmacokinetic Interaction Between Trospium Chloride After Intravenous (2 mg) and Oral Administration (30 mg) With Ranitidine (300 mg p.o.) as an Inhibitor of OCT1 and With Clarithromycin (500 mg p.o.) as an Inhibitor of P-glycoprotein in 24 Healthy Subjects Genotyped for OCT1
NCT03011463 is registered in ClinicalTrials.gov with Dr. R. Pfleger Chemische Fabrik GmbH as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Pharmacokinetic Interaction Between Trospium Chloride After Intravenous (2 mg) and Oral Administration (30 mg) With Ranitidine (300 mg p.o.) as an Inhibitor of OCT1 and With Clarithromycin (500 mg p.o.) as an Inhibitor of P-glycoprotein in 24 Healthy Subjects Genotyped for OCT1
- Lead sponsor
- Dr. R. Pfleger Chemische Fabrik GmbH
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- November 30, 2016
- Completion date
- March 31, 2017
- Enrollment
- 24 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
drug interaction potentiation, inhibition enzyme, pharmacokinetics